Charlson-Deyo comorbidity score groups of 1 (HR 1.22, 95% CI 1.06–1.41), 2 (HR 1.8, 95% CI 1.47–2.22), and 3 or more (HR 2.46, 95% CI 1.94–3.12) were associated with statistically significantly worse OS compared with the score 0 group, demonstrating a clear trend of decreasing survival as the comorbidity score increased.
In summary, women with consistent condom use not only had lower HPV DNA positivity rates both after 6 and 24 months, as compared to women with inconsistent condom use, but, additionally, they illustrated a decreasing trend for HPV DNA positivity rate over time (from 23% to 13%), while inconsistent users had an increasing HPV positivity rate (from 62% to 71%).
Nevertheless, HPV mRNA positivity rates for compliant women were again lower than incompliant ones, despite exhibiting an increasing trend longitudinally for both groups, a finding requiring further investigation.
In a multivariate regression analysis, a GLR > 92.72 [hazard ratio (HR) = 2.475, 95% confidence interval (CI): 1.502–4.078, p < 0.001] was identified as an independent predictors of long-term DSS prognosis, while CA19-9 > 145.35 U/mL (HR = 1.577, 95% CI: 0.966–2.572, p = 0.068) and the presence of symptoms (HR = 1.582, 95% CI: 0.974–2.568, p = 0.064) were expected to be marginally significant independent predictors of DSS prognosis ( Table 2 , Figure 1 ).
No significant difference in DFS was found between thymic carcinoma patients with and without pathogenic SNVs ( p = 0.190); however, the latter showed a trend towards a longer median DFS (16.0 vs. 30.0 months, respectively; Figure 2 ).
As such, the analysis of the optimal delta-radiomics features revealed an increasing trend of the feature values relevant to the two classes ( Figure 3 ).
The survival curves for the different disease stages (stage I/II/III compared to stage IV) showed a trend toward inferior OS for stage IV disease ( Supplementary Figure S2G,H ), as expected.
In our results, all textural features that were significant predictors for RFS on the multivariate analysis showed correlations with CD8 T lymphocyte infiltration with statistical significance or a marginally significant level, showing increased maximum SUV and intra-tumoral metabolic heterogeneity in patients with increased CD8 T lymphocyte infiltration.
[ 16 ], S-1 chemotherapy showed a trend toward a better five-year DFS in stage II (HR 1.85, 95% CI 0.69–4.92); however, there was no difference in the five-year DFS between the two regimens in stage III (HR 0.94, 95% CI 0.66–1.34).
Time-dependent leakage (Ktrans) measurements demonstrated an increasing trend prior to POD between T-1 and T-2 time points; however, the opposite was observed between T-2 and T-3.
Regarding survival, a favorable trend was found for the experimental arm; however, with a median follow-up of 20.6 months, the EFS outcomes were still immature (HR 0.76; 95% CI, 0.40 to 1.44) [ 63 ]. 3.3.
In contrast, treatment with the lower chemerin concentration (100 ng/mL) did not show significant changes in OVCAR-3 cell numbers but did show an increasing trend.
Concordant with CIBERSORT, not all STS tumors show low infiltration, but there is a clear trend indicating that T FH cells are more frequently found in the LTS samples ( Figure 1 G). 3.3.
A multivariate Cox regression identified high TROP2 expression together with lymph node metastases and an age older than 75 years as an independent negative prognostic factor for poor CSS, whereas CK7 reached borderline significance ( Figure 2 D). 3.3.